To lower cost burden, oncologists suggest smaller doses, but Keytruda says no
✨ AI Summary
🔊 جاري الاستماع
Keytruda was first approved by the US Food and Drug Administration (FDA) in 2014 for metastatic skin cancer and is now used across a host of cancers, raking in $29.5 billion in 2024.
